IN8bio

Save the Date: IN8bio’s Research & Development Day 2026, which will be held on May 21, 2026. This event will feature presentations on our clinical program in glioblastoma (GBM), including a clinical perspective from renowned neuro-oncologist Dr. David Reardon. We will also discuss our new gamma-delta T cell engager (TCE) platform targeting oncology and autoimmune diseases. 📍 This event will be held in person in New York City, with a virtual attendance option available for those joining remotely. $INAB

🔥Register today by visiting investors.in8bio.com and navigating to the “Events and Presentations” section. $INAB

Save the Date: IN8bio’s Research & Development Day 2026, which will be held on May 21, 2026. This event will feature presentations on our clinical program in glioblastoma (GBM), including a clinical perspective from renowned neuro-oncologist Dr. David Reardon. We will also discuss our new gamma-delta T cell engager (TCE) platform targeting oncology and autoimmune diseases. 📍 This event will be held in person in New York City, with a virtual attendance option available for those joining remotely. $INAB

Listen here: •open.spotify.com/episode/7pV0sl… •raisingbiotech.com/episode/s4-e4-… •podcasts.apple.com/us/podcast/s4-…

Our CEO, William Ho, joined Raising Biotech to discuss: • GLP-1 hype & biotech cycles • Capital allocation • Funding innovation outside the spotlight

Biotech moves in cycles. Capital clusters quickly around what feels “validated.” But that can leave other areas behind. $INAB

Read the full article here: genengnews.com/topics/cancer/…

Solid tumors remain one of the toughest challenges in cancer. Exciting new approaches are emerging, including ours, where we engineer immune cells to stay active alongside chemotherapy. Grateful to be featured by @GENbio. $INAB

Busy Friday in the IN8bio lab. Preclinical TCE work moving forward while the clinical team processes patient samples. Science doesn’t follow a schedule. We’re ready when patients are. $INAB

On International Women’s Day, we stand in solidarity with all the incredible women who have paved the way in STEM and those who will continue to inspire future generations. Today, we celebrate the trailblazers who never backed down from a challenge. Their perseverance has led to remarkable advancements in science that benefit us all. Thank you. #GiveToGain #IWD2026

Our CEO and Co-founder, William Ho, is presenting at the TD Cowen 46th Annual Conference today at 9:50 AM EST in Boston. Catch the live webcast here: investors.in8bio.com/news-events/ev… $INAB

@AndreaRilli @AndreaRilli, we obviously think the world of her as well! Thank you for your kind words. It's great to hear that our passion and dedication resonated with you. Stay tuned!

@In8bio Regarding Kate and the management of In8bio,every time I listened to them during an interview,I had the impression of being in front of honest and competent people,who put their great passion into their work and into achieving an ambitious goal: cancer ZERO. Keep it up.Thank you.

We are happy to announce that our President & COO, Dr. Kate Rochlin, will present at the Festival of Biologics USA 2026 on March 4th, at 12:30 pm PST. She will present on “Activating the Potential of Gamma Delta T-Cells: A Next-Generation TCE for Autoimmune & Oncology.” $INAB #CancerZero

We are happy to announce that our CEO and Co-founder, William Ho, will give a company presentation at the TD Cowen 46th Annual Health Care Conference on Monday, March 2, at 9:50 am EST. A live webcast and replay link will be available on the IN8bio website.  Read the full press release: bit.ly/4kVQEU6 $INAB @willhonyc

How we’re pushing innovation in oncology. We're just getting started $INAB (HT @ConferenceForum)

This is our path towards Cancer Zero $INAB (HT @ConferenceForum)

Welcome to the future of oncology $INAB

We are pleased to announce that our CEO and Co-founder, William Ho, will present at the IO360° Conference this Thursday, February 12th, at 1:20 PM EST. He will be presenting on IN8bio’s Unique DeltEx Drug-Resistant Immunotherapy (DRI) Approach to Solid Tumors & Results from Phase 1/2 Study in Newly Diagnosed GBM. Session: IO Clinical Advancements Plenary. Register Here: io360summit.com We hope to see you there! $INAB

Let’s make sure cancer stays losing $INAB

Huge shoutout to @RoyalFamily for showing up for cancer charities at the community level. Visibility, support, and presence matter. Onward to Cancer Zero! $INAB

Exciting news at IN8bio! We're proud to announce Kate Rochlin, Ph.D., as our new President and Chief Operating Officer!  “Kate has been instrumental in translating IN8bio’s strategy into disciplined execution,” said William Ho, Chief Executive Officer and Co-Founder of IN8bio. “I am confident that her promotion to President will further strengthen the organization.” Congratulations, Kate! 🎉  Read More: bit.ly/3ZKtxlP $INAB